Diabetes Centre, Heart and Diabetes Centre NRW, Ruhr University Bochum, Germany.
Int J Clin Pract. 2012 Apr;66(4):384-93. doi: 10.1111/j.1742-1241.2011.02886.x. Epub 2012 Jan 27.
Despite improvements in surgical revascularisation, limitations like anatomical factors or atherosclerosis limit the success of revascularisation in diabetic patients with critical limb ischaemia. Stem cells were shown to improve microcirculation in published studies. The aim of this study was to evaluate safety, feasibility and efficacy of transplantation of bone marrow derived cellular products regarding improvement in microcirculation and lowering of amputation rate.
Bone marrow mononuclear cells (BMCs) in comparison with expanded bone marrow cells enriched in CD90+ cells ('tissue repair cells', TRCs) were used in the treatment of diabetic ulcers to induce revascularisation. Diabetic foot patients with critical limb ischaemia without option for surgical or interventional revascularisation were eligible. Parameters examined were ABI, TcPO(2) , reactive hyperaemia and angiographic imaging before and after therapy.
Of 30 patients included in this trial, 24 were randomised to receive either BMCs or TRCs. The high number of drop-outs in the control group (4 of 6) led to exclusion from evaluation. A total of 22 patients entered treatment; one patient in the TRC group and two in the BMC group did not show wound healing during follow up, one patient in each treatment group died before reaching the end of the study; one after having achieved wound healing (BMC group), the other one without having achieved wound healing (TRC group). Thus, 18 patients showed wound healing after 45 weeks. The total number of applicated cells was 3.8 times lower in the TRC group, but TRC patients received significantly higher amounts of CD90+ cells. Improvement in microvascularisation was detected in some, but not all patients by angiography, TcPO(2) improved significantly compared with baseline in both therapy groups.
The transplantation of BMCs as well as TRCs proved to be safe and feasible. Improvements of microcirculation and complete wound healing were observed in the transplant groups.
尽管手术血运重建有所改善,但解剖因素或动脉粥样硬化等限制因素限制了糖尿病合并严重肢体缺血患者血运重建的成功率。已有研究表明,干细胞可改善微循环。本研究旨在评估骨髓源性细胞产品(包括骨髓单个核细胞(BMCs)和富含 CD90+细胞的扩增骨髓细胞,即“组织修复细胞”(TRCs))移植治疗糖尿病溃疡以诱导血运重建的安全性、可行性和疗效,从而改善微循环并降低截肢率。
将 BMCs 与富含 CD90+细胞的扩增骨髓细胞(“组织修复细胞”(TRCs))用于治疗糖尿病溃疡以诱导血运重建。纳入无手术或介入血运重建选择的严重肢体缺血的糖尿病足患者。治疗前后评估参数包括踝肱指数(ABI)、经皮氧分压(TcPO2)、反应性充血和血管造影成像。
在这项试验中,纳入了 30 例患者,其中 24 例随机接受 BMCs 或 TRCs 治疗。对照组(6 例中有 4 例)的失访率很高,导致无法进行评估。共有 22 例患者进入治疗;TRC 组 1 例和 BMC 组 2 例在随访期间未出现伤口愈合,每组各有 1 例患者在研究结束前死亡;其中 1 例在 BMC 组达到伤口愈合,另 1 例在 TRC 组未达到伤口愈合。因此,18 例患者在 45 周后伤口愈合。TRC 组应用细胞总数低 3.8 倍,但 TRC 患者接受的 CD90+细胞数量明显更高。血管造影显示部分患者(但非所有患者)的微血管生成得到改善,且两组的 TcPO2 与基线相比均显著改善。
BMCs 和 TRCs 的移植均被证明是安全可行的。移植组观察到微循环改善和完全伤口愈合。